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Abstract
Background: Metastasis to regional lymph nodes is a common step in the progression of cancer.
Recent evidence suggests that tumor production of CXCR4 promotes lymph node metastasis.
Nitric oxide (NO) may also increase metastatic ability in human cancers.
Methods: Nitrite/nitrate levels and functional CXCR4 expression were assessed in K1 and B-
CPAP papillary thyroid carcinoma (PTC) cells after induction and/or inhibition of NO synthesis.
CXCR4 expression was also analyzed in primary human PTC. The relationship between
nitrotyrosine levels, which are a biomarker for peroxynitrate formation from NO in vivo, CXCR4
expression, and lymph node status was also analyzed.
Results: Production of nitrite/nitrate and functional CXCR4 expression in both cell lines was
increased by treatment with the NO donor DETA NONOate. The NOS inhibitor L-NAME
eliminated this increase. Positive CXCR4 immunostaining was observed in 60.7% (34/56) of PTCs.
CXCR4 expression was significantly correlated with nitrotyrosine levels and lymph node metastasis
in human PTC.
Conclusion: Our data indicate that NO stimulates CXCR4 expression in vitro. Formation of the
NO biomarker nitrotyrosine was also correlated with CXCR4 expression and lymph node
metastasis in human PTC. NO may induce lymph node metastasis via CXCR4 induction in papillary
thyroid carcinoma.
Background
Nitric oxide (NO) is a pleiotropic regulator and inflam-
matory stimulant, critical to numerous biological proc-
esses, including vasodilatation, neurotransmission, and
macrophage-mediated immunity [1]. It also has both gen-
otoxic and metastasis-promotng properties. Increased NO
generation in cancer cells may contribute to tumor
hemangiogenesis or lymphangiogenesis by up-regulating
vascular endothelial growth factor (VEGF) [2], VEGF-C
[3], or VEGF-D [4]. The effects of NO are mediated in part
by its metabolites, such as peroxynitrite. Peroxynitrite can
oxidize and nitrate DNA and can also nitrate tyrosine in
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proteins to produce nitrotyrosine [5]. Thus the presence of
nitrotyrosine in tissues has been used as a biomarker for
peroxynitrite formation in vivo from NO.
Metastasis to regional lymph nodes is a common step in
the progression of cancer. Metastasis of cancer cells is a
complex process involving invasion, hemangiogenesis,
lymphangiogenesis, trafficking of cancer cells through
blood or lymph vessels, extravasations, organ-specific
homing, and growth. Recent evidence suggests that meta-
static cancer cells overexpress CXC chemokine receptor 4
(CXCR4), and that CXCR4 plays a critical role in homing
of cancer cells to specific metastatic sites[6]. The CXCR4
ligand CXCL12 was found to be expressed in liver, bone
marrow, lung, and lymph nodes. Furthermore, metastasis
of cancer cells to regional lymph nodes and lung in immu-
nodeficient mice were inhibited by a neutralizing anti-
body against CXCR4 [6]. However, how CXCR4
expression is regulated is largely unknown. We considered
the possibility that the inflammatory stimulant NO is
involved in the expression of CXCR4 in papillary thyroid
carcinoma (PTC) because NO has been shown to up-reg-
ulate the expression of prometastatic and proangiogenic
genes including VEGF [2], VEGF-C [3], and VEGF-D [4]. In
experimental tumor models, a contributory role of NO in
tumor metastasis has been also demonstrated [7]. In addi-
tion, signal-activated transcription factor NF-kappa B,
which is linked to NO signaling pathways, has been
shown to up-regulate the expression of CXCR4 and to
mediate CXCL12-induced T cell migration [8,9]. Further-
more approximately one third of PTCs show moderate to
marked lymphocytic infiltration. In most instances, this
probably represents a host reaction to the tumor; in oth-
ers, it may be due to a preexisting autoimmune thyroiditis
[10]. The presence of NO in tumor cells or the tumor
micro-environment may increase the metastatic ability of
PTC, in which many cases have inflammatory infiltration.
In this study, incubation of K1 and B-CPAP PTC cells with
an NO donor resulted in induction of functional CXCR4
expression. This induction was significantly inhibited by
addition of the NOS inhibitor L-NAME. In addition, we
investigated how CXCR4 expression relates to lymph
node metastasis and nitrotyrosine formation in PTC.
Methods
Cell culture
The K1 and B-CPAP PTC cell lines were purchased from
the European Collection of Cell Cultures (ECACC, Wilt-
shire, United Kingdom) and the German Collection of
Microorganisms and Cell Cultures (DSMZ, Braunschweig,
Germany), respectively. K1 cells were maintained at 37°C
in 5% CO2, as monolayers in tissue culture dishes con-
taining DMEM: Ham's F12 (Invitrogen, Tokyo, Japan)
supplemented with 10% heat-inactivated fetal calf serum
(FCS) (HyClone, South Logan, UT, USA) as described pre-
viously [4]. B-CPAP cells were maintained at 37°C in 5%
CO2, as monolayers in tissue culture dishes containing
DMEM (Invitrogen) supplemented with 10% heat-inacti-
vated FCS (HyClone). For the experiments, 6 cm tissue
culture plates (Corning, Corning, NY, USA) were seeded
with 3 × 105 cells in 3 ml of medium + 10% FCS. Medium
was changed (day 3), and when the cells were subconflu-
ent (day 5), 5 mM (B-CPAP) or 10 mM (K1) L-NAME
(Sigma-Aldrich, Tokyo, Japan), if administered, was
added 2 h before 1 mM DETA NONOate (Cayman Chem-
ical, Ann Arbor, MI, USA). These concentrations of L-
NAME or DETA NONOate had no effect on cell viability
as measured by the CellTiter 96 Aqueous One Solution
Cell Proliferation Assay (Promega, Madison, WI, USA)
(data not shown).
Measurement of nitrate/nitrite production
Measurement of nitrate/nitrite production was performed
as described previously [4]. After DETA NONOate admin-
istration, cells were incubated for 4, 6, 8, 12, 16, and 24 h.
The supernatants were collected and centrifuged to
remove cell debris. The amount of nitrate/nitrite was
determined using a Nitrate/Nitrite Fluorometric Assay Kit
(Cayman Chemical) [11].
Determination of CXCR4 mRNA production
After DETA NONOate administration, cells were incu-
bated for 4, 6, 8, 12, 16, and 24 h. Total RNA was extracted
using Trizol (Invitrogen) according to the protocol pro-
vided by the manufacturer. After DNase treatment using
DNA-free™ (Ambion, Austin, TX, USA), mRNA was
reverse-transcribed for single strand cDNA using Oligo-
(dT)20  primer and Thermoscript (Invitrogen, Tokyo,
Japan) as described previously[4]. CXCR4 transcription
was measured by quantitative real-time PCR of the result-
ing cDNA, using universal TaqMan PCR reagents, and an
ABI Prism 7000 sequence detector equipped with a 96-
well thermal cycler (Perkin-Elmer Applied Biosystems,
Foster City, CA, USA). The primer and probe mixtures for
CXCR4 and GAPDH were purchased from Perkin-Elmer
Applied Biosystems, and PCR was carried out according to
the manufacturer's protocol. CXCR4 mRNA expression
was quantitated relative to control cells (treated with nei-
ther DETA NONOate or L-NAME) based on a real-time
PCR standard curve constructed with serially diluted solu-
tions of a CXCR4 cDNA-containing plasmid as templates.
All experiments were performed in triplicate, although
amplification results have been shown to be very consist-
ent and tube-to-tube-variability very low. Mean values
were used for statistical testing. The GAPDH transcript lev-
els of each sample were also monitored, which confirmed
that tube-to-tube-variability was very low (data not
shown).BMC Cancer 2008, 8:274 http://www.biomedcentral.com/1471-2407/8/274
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Determination of CXCR4 protein production
For the determination of CXCR4 protein production, cells
were incubated for 8 h (K1) or 12 h (B-CPAP) after DETA
NONOate administration, and harvested as described
above. Cell lysates were prepared using T-PER™ Tissue
Protein Extraction Kit (Pierce, Rockford, IL, USA) contain-
ing Halt™ Protease Inhibitor Cocktail (Pierce) as described
previously [4]. For Western blot analysis of CXCR4, 30
microgram samples of whole cell lysate were separated by
electrophoresis on 10–20% SDS polyacrylamide gels and
transferred to PVDF membrane by electroblotting. The
membrane was blocked with 5% skim milk in PBS for 1 h
at room temperature, incubated overnight with anti-
human CXCR4 rabbit antibody (Abcam Ltd., Cambridge,
UK), rinsed with PBS, and labeled with peroxidase-conju-
gated anti-rabbit secondary antibosdy (Dako Cytomation,
Denmark) for 1 h at room temperature. The signals were
visualized using the LumiGLO Reserve chemilumines-
cence substrate kit (KPL, Inc, Gaithersburg, MD, USA) and
recorded by luminocapture (ATTO, Tokyo, Japan). Anti-
beta-2-microglobulin antibody (Dako Cytomation) was
used for the internal control. To compare levels of pro-
teins, the density of each band was measured by densit-
ometry.
Chemoinvasion assay
Chemoinvasion assay of each cell type was assessed in BD
Matrigel™ Invasion Chamber 24-well plates (BD Bio-
sciences, Bedford, MA, USA). Briefly, the upper compart-
ment of the chamber was seeded with 2 × 104 cells, and
the lower compartment of the chamber was loaded with
medium. Medium in the upper compartment of the
chamber was changed (day 3), and 5 mM (B-CPAP) or 10
mM (K1) L-NAME, if administered, was added 2 h before
1 mM DETA NONOate. At the same time, the lower com-
partment of the chamber was loaded with different con-
centrations of recombinant human CXCL12 (rhCXCL12)
or without rhCXCL12 (R&D Systems, Minneapolis, MN,
USA). The two compartments were separated by a
Matrigel-coated membrane (10 micrometer thickness and
8 micrometer pore size). Uncoated membranes were used
as a control for non-invasive cell migration, in accordance
with the manufacturer's directions. After the incubation
(day5), the chamber was removed, and cells that had
migrated to the bottom of the membrane were fixed and
stained in Cyto Quick Solution (Muto Pure Chemical,
Tokyo, Japan) and counted by light microscopy. The per-
centage of invading cells after incubation (% Invasion)
was calculated as (Matrigel)/(Control membrane),
according to the manufacturer's protocol.
Patients and tumor samples
After investigational review board approval by the
Wakayama Medical University Medical Ethics Committee
and informed consent was obtained, paraffin-embedded
archival specimens from 56 patients with PTC, who were
diagnosed and treated in Kuma Hospital, Japan in 2003,
were examined immunohistochemically. None of these
cases had a family history of thyroid cancer or malig-
nancy. The patients had received total or subtotal thyroid-
ectomy with regional lymphadenectomy (central neck
dissection, lateral neck dissection, superior mediastinal
dissection, or a combination of the above). All sections of
the excised tumors were histologically evaluated by 3
pathologists (HY, RK, and YN). Of the 56 patients
selected, 49 had classical PTC, 3 had a poorly differenti-
ated form, and 4 had a follicular variant as assessed by his-
topathology. Patients with multifocality were excluded.
Patients and tumor characteristics are shown in Table 1.
The median age at surgery for the selected patients was
49.5 years (range, 16–76 years). All of the patients have
been followed-up and none has had a recurrence.
Immunohistochemistry
For immunostaining, paraffin sections of 4-micrometer
thickness were de-paraffinized, placed in a solution of
97% methanol and 3% hydrogen peroxide for 5 min, then
autoclaved for antigen retrieval. After washing in PBS, the
slides were treated for 20 min with Protein Block Serum-
free (DAKO Cytomation, Carpinteria, CA, USA). This was
followed by an overnight incubation at 4°C. in a humid-
ified chamber with a 1:30 diluted anti-human CXCR4 rab-
bit antibody (Abcam). After the overnight treatment, to
avoid the nonspecific biotin reaction, we used Histofine
Simple Stain MAX PO (NICHIREI, Tokyo, Japan) as the
second antibody for 60 min according to the manufac-
turer's instructions. Color was developed using diami-
nobenzidine with 0.01% hydrogen peroxide.
Hematoxylin was used as a counterstain. For the negative
control, all reagents except for the primary antibody were
used.
The immunohistochemical scoring was performed
blindly by 3 pathologists (HY, RK, and YN) who had no
clinical knowledge of the patients. The immunostained
sections were scanned by light-microscopy. Cytoplasmic
labeling of tumor cells was classified as either negative (if
no staining or positive staining was present in <10% of
tumor cells) or positive (if over 10% of tumor cells stained
positively).
Statistics
The effects of drug treatment were analyzed by ANOVA
followed by Student's t test. Fisher's exact test was used to
examine the association between CXCR4 immunoreactiv-
ity and other clinicopathological factors. A p value less
than 0.05 was considered significant. A software package
(JMP IN 5.1.1, SAS Institute, Cary, NC, USA) was used for
all statistical testing and management of the database.BMC Cancer 2008, 8:274 http://www.biomedcentral.com/1471-2407/8/274
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Results
Effects of NO on CXCR4 expression
To examine the effect of NO on CXCR4 induction, K1 and
B-CPAP cells were treated with the NO donor DETA NON-
Oate. A significant increase in nitrate/nitrite production in
the supernatants after stimulation with DETA NONOate
was observed (Figure 1A). Pre-treatment of the cells with
the NOS inhibitor L-NAME significantly inhibited this
increase. As shown in Figures 1B and 1C, a significant
increase in CXCR4 mRNA and protein expression was
observed after stimulation with DETA NONOate. Pre-
treatment with L-NAME substantially inhibited the effects
of DETA NONOate on CXCR4 mRNA and protein expres-
sion.
NO regulates CXCL12-mediated chemoinvasion
To determine the role of NO in cellular response to the
CXCR4 ligand CXCL12, we examined the effect of L-
NAME on rhCXCL12- and DETA NONOate-induced in-
vitro Matrigel invasion by K1 and B-CPAP cells (Figure 2).
rhCXCL12 produced a dose-dependent increase in inva-
siveness, which was inhibited in cells pretreated with L-
NAME.
CXCR4 expression in papillary thyroid carcinoma tissue
In this study, immunohistochemical localization of
CXCR4 protein was cytoplasmic (Figure 3A). In these
cases, tumor CXCR4 expression was homogenous. In
some cases carcinoma cells showed positive staining in
the membrane in addition to cytoplasmic staining (Figure
3B). According to the criteria for CXCR4 immunohisto-
chemical evaluation, CXCR4 positive staining was
detected in 34 cases (60.7%). In the tumor in which
CXCR4 immunodetection are unreactive, staining for
CXCR4 occurred in inflammatory cells (Figure 3C). In
contrast, very little or no staining was observed in normal
thyroid epithelium (data not shown).
CXCR4 expression is correlated with nitrotyrosine levels 
and lymph node metastasis
We have previously reported that nitrotyrosine formation
was detected by immunohistochemistry in all PTCs [4].
The intensity of nitrotyrosine immunostaining was evalu-
ated by dividing the cytoplasmic staining reaction into
four groups: 1 = weak; 2 = moderate; 3 = strong; and 4 =
very strong. The fraction of immunostainined cells was
evaluated as follows: 1 = <25%; 2 = 25–50%; 3 = 50–75%;
and 4 = >75% of tumor cells showing cytoplasmic stain-
ing. These summed scores were then divided into two
groups as low-grade (2–4) and high-grade (5–8) for statis-
tical testing. High-grade nitrotyrosine staining was
observed in 51.8% (29/56) of the PTCs, and its expression
was significantly correlated with lymph node metastasis
(p = 0.0173), as shown in Table 1. CXCR4 expression was
correlated with high-grade nitrotyrosine staining (p <
0.001) and lymph node metastasis (p = 0.0116). There
was no significant correlation between CXCR4 expression
and other clinicopathological factors.
Discussion
NO, an inorganic free radical gas, is an important signal-
ing molecule and bioactive agent that mediates vasodila-
Table 1: Clinico-pathological data for 56 papillary thyroid carcinoma cases and relationship between CXCR4 expression and 
covariates
Factors CXCR4 expression p value
Negative Positive
Age <45 10 11 0.4009
45 12 23
Sex Male 4 3 0.4149
Female 18 31
Histology Well Diff. 20 29 0.1989
Follicular variant 2 2
Poorly Diff. 0 3
Tumor size pT1 1 6 0.1585
pT2 16 21
pT3 3 1
pT4 2 6
Lymph node Metastasis pN0 10 4 0.0116
pN1a 3 12
pN1b 9 18
Nitrotyrosine Levels Low grade 19 8 <0.001
High grade 3 26
*Tumor size, lymph node metastasis, and distant metastasis were classified according to the TNM classification of the UICC, 2002
*Fisher's exact test was used to examine the association between CXCR4 expression and covariates.
*Diff.: DifferentiatedBMC Cancer 2008, 8:274 http://www.biomedcentral.com/1471-2407/8/274
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tation and various other actions such as neurotransmission
and host defense [1]. NO produced by macrophages can have
antibacterial and antitumor functions, however, chronic
induction of NO and NO synthase may contribute to many
pathological processes including inflammation and cancer
[12,13]. In experimental tumor models, a contributory role
of NO in tumor metastasis has been also demonstrated [2,7].
Previous reports have shown that NO induces lymphang-
iogenic factor VEGF-C or VEGF-D expression in vitro and in
vivo, and may play an important role in lymph node metas-
tasis in cancer [3,4,14]. VEGF-D in particular may have an
important role in particular for lymph node metastasis in
PTCs [15]. CXCR4 is the physiological receptor for
CXCL12, which belongs to a chemokine family that has
potent chemotactic activity for lymphocytes. It is well
known that peripheral lymphocytes preferentially local-
ize to peripheral lymphoid tissues, such as lymph nodes;
this is called the homing phenomenon [16]. Recent evi-
dence suggests that metastatic cancer cells overexpress
CXCR4 and that this receptor plays a critical role in hom-
ing of cancer cells to specific metastatic sites [6].
In this study, the NO donor DETA NONOate induced
CXCR4 mRNA and protein expression in the K1 and B-
CPAP PTC cell lines. In chemoinvasion assays, rhCXCL12-
induced invasion was observed in both cell lines after
Effects of NO on CXCR4 expression Figure 1
Effects of NO on CXCR4 expression. Effects of DETA NONOate in the presence or absence of L-NAME on (A) nitrate/
nitrite production, (B) CXCR4 mRNA expression, and (C) CXCR4 protein expression. K1 and B-CPAP cells were treated 
with 1 mM DETA NONOate in the presence or absence of L-NAME for various time periods and prepared for (A) measure-
ment of nitrate/nitrite production, (B) real-time RT-PCR analysis, and (C) western blot analysis, as described in Materials and 
Methods. Determinations were performed in triplicate and expressed as mean of three experiments ± SE. (A) Control indi-
cates cells with no treatment. (B-C) Data was expressed as ratio of mRNA or protein levels relative to control (untreated) 
cells. * indicates significant difference (p < 0.05) from control and/or L-NAME-treated cells.
AB
CBMC Cancer 2008, 8:274 http://www.biomedcentral.com/1471-2407/8/274
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treatment with DETA NONOate, indicating that DETA
NONOate stimulated functional CXCR4 expression. All
these increases were significantly inhibited in the presence
of the NOS inhibitor L-NAME. A significant increase in
nitrate/nitrite production in the supernatants after stimu-
lation with DETA NONOate was also observed, and treat-
ment of cells with L-NAME substantially inhibited this
increase as well. Our results suggest that CXCR4 expres-
sion may be regulated by NO in these PTC cell lines.
In addition, positive CXCR4 immunostaining was
observed in 60.7% (34/56) of PTCs. An earlier report of
CXCR4 expression in cultured cell lines obtained origi-
nally from PTC also supports our present observation
[17]. In the present study, immunohistochemistry
revealed that CXCR4 expression was significantly corre-
lated with nitrotyrosine levels and lymph node metastasis
in human PTC tumor samples. Our findings suggest that
CXCR4 expression in human PTC may be associated with
nitrotyrosine formation and lymph node metastasis. In
this study, the NO donor DETA NONOate induced func-
CXCL12 induced the chemoinvasion of papillary thyroid cancer cells Figure 2
CXCL12 induced the chemoinvasion of papillary thyroid cancer cells. Cells were seeded into the upper compart-
ments of Matrigel Invasion Chambers as described in Materials and Methods. Uncoated or Matrigel-coated membranes sepa-
rated the upper compartments from lower compartments containing the indicated concentrations of CXCL12. Cells were 
treated with DETA NONOate with or without L-NAME. Two days later, cells that had migrated to the bottom of the mem-
brane were stained and counted. The percentage of invasive cells (% Invasion) was calculated as the number of cells penetrating 
the Matrigel-coated membranes divided by the number penetrating the uncoated membranes. Determinations were performed 
in triplicate and expressed as mean of three experiments ± SE. * indicates significant difference (p < 0.05) from L-NAME-
treated cells.
K1 B-CPAPBMC Cancer 2008, 8:274 http://www.biomedcentral.com/1471-2407/8/274
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tional CXCR4 protein expression in the both K1 and B-
CPAP PTC cell lines. These results may support the corre-
lation between CXCR4 expression and nitrotyrosine for-
mation in human PTC tumor samples. Consistent with
up-regulation of CXCR4 expression by NO, 70% of the
low nitrotyrosine patients showed negative CXCR4 stain-
ing. However, 10% of the high nitrotyrosine patients also
showed negative cytoplasmic staining. Although this is
lower than the overall percentage showing negative cyto-
plasmic staining (48%), it indicates that other factors reg-
ulate CXCR4 expression in these patients. As it has been
reported previously that CXCR4 expression is induced by
other factors, such as NF-kappa B [8], c-erbB-2 [18], or
hypoxia-inducible factor 1 [19], these factors may induce
CXCR4 expression in the cases with low levels of nitroty-
rosine.
Recently Balabanian et al demonstrated that CXCL12 can
also be a ligand for CXCR7 [20]. A previous report also
showed that CXCR7 expression in tumor cells enhances
cell growth, survival, and adhesion, and also causes tumor
growth in vivo in animal models [21]. Since CXCL12 is
expressed preferentially in lymph nodes [6], this may sup-
port our finding that CXCR4 expression was significantly
correlated with lymph node metastasis in human PTC
tumor samples. As CXCR7 expression promotes cancer
metastasis in various human cancers [22,23], it would be
also important to investigate the role of CXCR7 in PTC in
the future study.
Conclusion
Nitric oxide induces functional CXCR4 in vitro, and levels
of the NO marker nitrotyrosine are correlated with CXCR4
expression and lymph node metastasis in human papil-
CXCR4 expression in human papillary thyroid carcinoma tissue Figure 3
CXCR4 expression in human papillary thyroid carcinoma tissue. (A) immunohistochemical localization of CXCR4 
protein was cytoplasmic. (B) In some cases carcinoma cells showed positive staining in the membrane. (C) In the tumor in 
which CXCR4 immunodetection are unreactive, staining for CXCR4 occurred in inflammatory cells.BMC Cancer 2008, 8:274 http://www.biomedcentral.com/1471-2407/8/274
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lary thyroid carcinoma. NO may play an important role in
metastasis of this cancer via CXCR4 induction.
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